OptimizeRx appoints Edward Stelmakh CFO/COO; Doug Baker transitions to EVP of finance

OptimizeRx Corp

Edward Stelmakh named CFO/COO effective Oct 11, 2021; Doug Baker becomes EVP of finance and accounting.
Stelmakh's annual base salary set at $425,000; target bonus 50% of base; one-time equity grant valued at $3.0 million.
Stelmakh brings 30+ years pharma experience, most recently as CFO/COO at Otsuka America Pharmaceuticals.
Severance includes 12 months base salary if terminated without cause, plus COBRA coverage for 12 months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Douglas P. Baker

EVP of finance and accounting

OPRX · OptimizeRx Corp

Effective: 2021-10-11
Successor: Edward Stelmakh
Filed: September 30, 2021, 7:59 PM ET

On September 24, 2021, the Company and Douglas P. Baker, the Company’s current Chief Financial Officer, agreed that Mr. Baker will transition into the position of EVP of finance and accounting.

Appointed

Edward Stelmakh

Chief Financial Officer/Chief Operations Officer

OPRX · OptimizeRx Corp

Effective: 2021-10-11
Filed: September 30, 2021, 7:59 PM ET

On September 30, 2021, OptimizeRx Corporation (the “Company”) announced that Edward Stelmakh has been appointed to serve as the Company’s Chief Financial Officer/Chief Operations Officer, effective as of October 11, 2021 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas P. Baker changed role as EVP of finance and accounting at OptimizeRx Corp.

Action: transitioned
Role: EVP of finance and accounting

Exact text from the filing

On September 24, 2021, the Company and Douglas P. Baker, the Company’s current Chief Financial Officer, agreed that Mr. Baker will transition into the position of EVP of finance and accounting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward Stelmakh was appointed as Chief Financial Officer/Chief Operations Officer at OptimizeRx Corp.

Action: appointed
Role: Chief Financial Officer/Chief Operations Officer

Exact text from the filing

On September 30, 2021, OptimizeRx Corporation (the “Company”) announced that Edward Stelmakh has been appointed to serve as the Company’s Chief Financial Officer/Chief Operations Officer, effective as of October 11, 2021 (the “Effective Date”).

View on SEC.gov

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-21-050817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.